Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q3 2025 · 10-Q
Revenue$2.26K$2.26K−94.6% vs Q3 2024 Net Income-$3.56M-$3.56MN/M vs Q3 2024 EPS Diluted-$0.28-$0.28N/M vs Q3 2024 Operating Income-$3,672,148N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$616,837N/M Margins · derivedOperating margin-162340.8%−151112.1 pt vs Q3 2024
Net margin-157505.1%−146225.7 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end